(Q39348241)

11 September 2017

title

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome (English)

1 reference

11 September 2017

0 references

Bifidobacterium infantis

object named as

Bifidobacterium infantis

1 reference

8

1 reference

11 September 2017

Peter J Whorwell

1

0 references

Duane Charbonneau

5

object named as

Duane Charbonneau

1 reference

11 September 2017

9

Eamonn M M Quigley

1 reference

11 September 2017

Linda Altringer

2

1 reference

11 September 2017

Jorge Morel

3

1 reference

11 September 2017

Yvonne Bond

4

1 reference

11 September 2017

Liam O'Mahony

6

1 reference

11 September 2017

Barry Kiely

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

The American Journal of Gastroenterology

11 September 2017

published in

1 reference

11 September 2017

volume

101

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1581-1590

1 reference

Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Serotoninergic neuroenteric modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

The use of probiotics in functional bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

From comic relief to real understanding; how intestinal gas causes symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

10.1111/J.1572-0241.2006.00734.X

21 January 2018

Identifiers

DOI

1 reference

release_4ki4mvno6bcfxad4fpnrvbhkey

11 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4ki4mvno6bcfxad4fpnrvbhkey

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference